National

The daily dose: October 29, 2021

Our Bureau October 29 | Updated on October 29, 2021

A health worker administers a dose of Covid-19 vaccine to a beneficiary at a vaccination centre in Kolkata, Friday, Oct 22   -  PTI

Here is a compilation of daily Covid-19 stories

#Covaxin dialogues: WHO top-brass say they are in touch with Bharat Biotech and are hopeful of an expert recommendation to the WHO, next week.

https://www.thehindubusinessline.com/news/science/final-decision-next-week-from-expert-panel-reviewing-covaxin-who/article37218811.ece

#India remains hopeful: Meanwhile, the Centre said it was hopeful that Covaxin would get WHO approval soon as discussions were making progress, according to Foreign Secretary Harsh Vardhan Shringla.

https://www.thehindubusinessline.com/news/national/covaxin-may-get-who-approval-soon-as-discussions-are-progressing-says-shringla/article37219877.ece

# US foray: Staying with Covaxin - Ocugen Inc, the US partner of Bharat Biotech has approached the US Food and Drug Administration (FDA) for phase 3 studies in the US.

https://www.thehindubusinessline.com/news/ocugen-seeks-usfda-nod-for-phase-3-trials-of-covaxin/article37206495.ece

#Kerala spike: While there are no explanations from Centre or State, Kerala is reporting a spike in numbers that is pushing up the national tally as well.

https://www.thehindubusinessline.com/todays-paper/tp-others/tp-variety/article37223648.ece

# Russia’s spike: Moscow city authorities have ordered most people to stay off work for at least 11 days to stem coronavirus infections, as new daily cases and deaths from Covid-19 in Russia surged to all-time highs.

https://www.thehindubusinessline.com/news/world/moscow-shuts-most-workplaces-as-infections-deaths-soar/article37225244.ece

Published on October 29, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

vaccines and immunisation
WHO
coronavirus
Covid-19
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.

You May Also Like